Actinium Pharmaceuticals, Inc.

Leadership Team

View Bio
Paul Diamond, Ph.D., Esq.

Paul Diamond, Ph.D., Esq.

Vice President, Legal and Intellectual Property Counsel

Paul Diamond, Ph.D., Esq.

Paul Diamond, Ph.D., Esq.

Vice President, Legal and Intellectual Property Counsel

Paul Diamond was appointed Vice President, Patent and Legal Counsel in July 2021.  He brings over twenty years of experience counseling life science companies on complex patent and commercial matters.  Prior to joining Actinium Pharmaceuticals, Paul led the in-house legal team at a publicly traded clinical diagnostics company.  He has practiced with the intellectual property group of global law firm White & Case LLP and at a number of nationally recognized law firms.   Paul received a J.D. from Fordham University School of Law, a Ph.D. (Molecular and Cellular Biology) from Harvard University, and a B.A. (Biology) from the Johns Hopkins University.

View Bio
Jenny Hsieh

Jenny Hsieh

Chief Strategy Officer

Jenny Hsieh

Jenny Hsieh

Chief Strategy Officer

Jenny has nearly two decades of experience in leading and developing corporate strategies across the healthcare and life sciences industries. Prior to joining Actinium, Jenny was the Head of Corporate Strategy at Immunomedics and helped transform the clinical-stage company into a commercial organization. Following its FDA approval of Trodelvy®, Immunomedics was acquired by Gilead Sciences for $21 billion. Previously, she was the Director of Corporate Strategy at Quest Diagnostics and a management consultant at several firms, where she advised healthcare and life sciences companies on their strategic plans to drive innovation and meaningful change in the industry. She has a BA from the University of Pennsylvania, an MBA from NYU's Stern School of Business and an MPA from NYU's Wagner Graduate School of Public Service.

View Bio
Steve O'Loughlin

Steve O'Loughlin

Chief Financial Officer

Steve O'Loughlin

Steve O'Loughlin

Chief Financial Officer

Steve joined Actinium in October 2015 as Vice President, Finance and Corporate Development and was named Principal Financial Officer in May 2017 and Chief Financial Officer in July 2020. Steve possesses nearly fifteen years of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. Prior to Actinium, from June 2015 to October 2015, Steve worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Steve held the position of Vice President, Corporate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences company developing and commercializing mass spectrometry imaging and bioanalytic technologies and services. Previously, From June 2010 to June 2012, Steve held corporate development positions with Caliber I.D., (formerly Lucid, Inc.) a publicly traded company developing and commercializing VivaScope ®, an FDA cleared diagnostic device for the non-invasive assessment of the skin for skin cancer and other dermatologic conditions. Steve previously worked in investment banking at Jesup & Lamont where he focused on the biotechnology and life sciences industries. Steve has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey.

View Bio
Monideepa Roy, Ph.D.

Monideepa Roy, Ph.D.

Senior Vice President, Corporate Development – R&D

Monideepa Roy, Ph.D.

Monideepa Roy, Ph.D.

Senior Vice President, Corporate Development – R&D

Monideepa leads corporate development initiatives at Actinium, driving business outcomes around R&D efforts. Before joining Actinium, she was Founder and interim CEO of Akamara Therapeutics, Inc., an early-stage oncology drug development company. Prior to Akamara, she was a founding member of Invictus Oncology, developing novel I/O and conjugated antibody therapies. Before moving to industry, Monideepa was a Lecturer at Harvard University, a Leukemia and Lymphoma Society Special Fellow at Brigham and Women’s Hospital and Research Fellow at Harvard Medical School where she was funded by the US Department of Defense and was awarded the first Thomas Gill Prize for Research Excellence. She received her Ph.D. in Molecular Biology from Jawaharlal Nehru University, New Delhi, Master's in Biophysics and Molecular Biology from the University College of Science and Bachelor's degree in Human Physiology (Honors) from Presidency College, Calcutta.

View Bio
Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board

Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board

Sandesh has 25+ years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Sandesh was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Sandesh has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Sandesh was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents related to use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.

View Bio
Gary Siegel

Gary Siegel

Vice President, Controller

Gary Siegel

Gary Siegel

Vice President, Controller

Gary is responsible for the preparation of the Company’s financial reporting, including reports filed with the Securities and Exchange Commission, or SEC. Gary has many years of experience working for public companies. Prior to joining Actinium, he was Controller at Bellerophon Therapeutics, Inc., a public medical device company, and prior to that, he was Vice President Finance of Cogentix Medical, Inc., a public medical device company. From 2003 to 2013, Gary was with Genta Incorporated, a public biopharmaceutical company, where he progressed to be Vice President-Finance and Principal Financial Officer. Earlier in his career, Gary had a number of positions at Pfizer Inc. Gary has an MBA from Carnegie-Mellon University.

View Bio
Madhuri Vusirikala, M.D.

Madhuri Vusirikala, M.D.

Vice President, Clinical Development BMT and Cellular Therapy

Madhuri Vusirikala, M.D.

Madhuri Vusirikala, M.D.

Vice President, Clinical Development BMT and Cellular Therapy

Madhuri is an accomplished bone marrow transplant physician and hematologist with over 20 years of clinical experience. She is board certified in internal medicine, hematology and oncology. Madhuri joins Actinium from UT Southwestern Medical Center in Dallas, Texas, where she has been a Professor of Internal Medicine in the Division of Hematology/Oncology and Medical Director of the Adult Allogeneic Bone Marrow Transplant Program. She specialized in managing a variety of hematologic malignancies and performing allogeneic bone marrow transplants for these patients when indicated. She also served as primary investigator for most of the clinical trials at UT Southwestern related to BMT. Madhuri earned her medical degree (M.B.B.S.) at India’s Lady Hardinge Medical College before completing an internal medicine internship at Maulana Azad Medical College-Delhi University and an internal medicine internship and residency at The State University of New York, Syracuse. She also completed a hematology and oncology fellowship at the University of Pittsburgh and an advanced fellowship in bone marrow transplantation at Vanderbilt University Medical Center. Madhuri is a member of the American Society of Hematology, American Society of Transplantation and Cellular Therapy. She serves as a member on the NCCN panels for Hematopoietic Cell Transplantation and Acute Lymphoblastic Leukemia committees.

Email Sign Up

Receive the latest news, events and updates!

Sign Up Now